ARS Pharmaceuticals, Inc. (SPRY)

ARS Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	39.86	50.82	70.97	210.52	60.06	24.52
Short-Term Investments	235.86	263.21	157.39	63.86	-	-
Cash & Short-Term Investments	275.73	314.02	228.36	274.38	60.06	24.52
Cash Growth	23.29%	37.51%	-16.77%	356.82%	144.94%	-
Accounts Receivable	9.3	8.18	-	-	-	0.38
Other Receivables	-	0.99	0.69	1.01	0	0
Receivables	9.3	9.16	0.69	1.01	0	0.38
Inventory	7.27	5.21	-	-	-	-
Prepaid Expenses	11.56	4.67	2.03	2.31	0.67	1.48
Other Current Assets	-	1.23	0.65	-	-	-
Total Current Assets	303.86	334.3	231.73	277.7	60.73	26.38
Property, Plant & Equipment	1.15	1.07	0.82	0.77	0.69	0.02
Other Intangible Assets	7.24	7.69	0.62	-	-	-
Other Long-Term Assets	15.07	8.11	0.02	2.96	0.02	0
Total Assets	327.32	351.15	233.19	281.44	61.45	26.41
Accounts Payable	27.01	14.13	0.76	1.66	1.79	1.22
Accrued Expenses	-	4.15	0.36	2.1	1.3	0.84
Current Portion of Long-Term Debt	-	-	-	-	3.48	2.56
Current Portion of Leases	0.07	0.04	0.24	0.23	0.14	-
Current Income Taxes Payable	-	-	-	0.17	-	-
Current Unearned Revenue	0.54	0.56	-	0.28	1.46	3.52
Other Current Liabilities	-	4.57	1.04	1	0.02	0.08
Total Current Liabilities	27.62	23.44	2.39	5.44	8.19	8.21
Long-Term Debt	69.38	69.38	-	-	4.93	7.46
Long-Term Leases	-	-	0.04	0.25	0.48	-
Long-Term Unearned Revenue	1.34	1.53	-	2.85	3	3.44
Other Long-Term Liabilities	-	-	-	-	0.08	0.11
Total Liabilities	98.34	94.36	2.43	8.55	16.68	19.23
Common Stock	0.01	0.01	0.01	0.01	0	0.22
Additional Paid-In Capital	386.14	379.87	362	349.41	10.98	7.74
Retained Earnings	-157.25	-123.31	-131.3	-76.94	-42.26	-22.01
Comprehensive Income & Other	0.07	0.22	0.05	0.41	-	-
Total Common Equity	228.97	256.8	230.76	272.89	-31.27	-14.05
Shareholders' Equity	228.97	256.8	230.76	272.89	44.77	7.18
Total Liabilities & Equity	327.32	351.15	233.19	281.44	61.45	26.41
Total Debt	69.46	69.43	0.27	0.48	9.03	10.02
Net Cash (Debt)	206.27	244.6	228.09	273.9	51.03	14.5
Net Cash Growth	-7.67%	7.24%	-16.73%	436.74%	251.86%	-
Net Cash Per Share	2.12	2.39	2.40	6.86	1.77	0.72
Filing Date Shares Outstanding	98.21	98.12	96.5	94.4	25.7	20.22
Total Common Shares Outstanding	98.13	97.95	96.41	93.94	25.7	20.22
Working Capital	276.24	310.86	229.34	272.26	52.54	18.17
Book Value Per Share	2.33	2.62	2.39	2.90	-1.22	-0.70
Tangible Book Value	221.73	249.11	230.14	272.89	-31.27	-14.05
Tangible Book Value Per Share	2.26	2.54	2.39	2.90	-1.22	-0.70
Machinery	-	1.21	0.67	0.38	0.09	0.03
Leasehold Improvements	-	0.02	0.02	-	-	-

Updated May 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q